Welcome to LookChem.com Sign In|Join Free

CAS

  • or

129-03-3

Post Buying Request

129-03-3 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

129-03-3 Usage

Description

Cyproheptadine has antianaphylactic activity that is associated with its ability to slow down the release of histamine and other mediators from fat cells.

Originator

Periactin,Merck Sharp and Dohme,US,1961

Uses

Different sources of media describe the Uses of 129-03-3 differently. You can refer to the following data:
1. Antihistaminic; antipruritic.
2. It is mainly used for treating bronchial asthma attacks, allergic bronchitis, rhinitis, and allergic skin reactions as well as in adjuvant therapy for anaphylactic reactions. Synonyms of this drug are periactin and vimicon.

Definition

ChEBI: The product resulting from the formal oxidative coupling of position 5 of 5H-dibenzo[a,d]cycloheptene with position 4 of 1-methylpiperidine resulting in the formation of a double bond between the two fragments. t is a sedating antihistamine with antimuscarinic and calcium-channel blocking actions. It is used (particularly as the hydrochloride sesquihydrate) for the relief of allergic conditions including rhinitis, conjunctivitis due to inhalant allergens and food , urticaria and angioedema, and in pruritic skin disorders. Unlike other antihistamines, it is also a seratonin receptor antagonist, making it useful in conditions such as vascular headache and anorexia.

Manufacturing Process

(A) Preparation of 1-Methyl-4-Piperidyl-Magnesium Chloride: Magnesium turnings (5.45 g, 0.22 g-atom) were placed in a 500 ml 3-necked flask provided with a condenser, Hershberg stirrer and dropping funnel and protected with a drying tube. An atmosphere of dry nitrogen was maintained in the apparatus throughout the reaction. The magnesium was covered with 20 ml of dry tetrahydrofuran. A crystal of iodine and 1.2 g of ethyl bromide were added and after the reaction had subsided (formation of ethylmagnesium bromide) a solution of 29.4 g (0.22 mol) of 4-chloro-1-methyl-piperidine in dry tetrahydrofuran (total volume, 103 ml) was added dropwise at such a rate that gentle reflux was maintained.The solution of 4-chloro-1-methylpiperidine in tetrahydrofuran was dried over calcium hydride at ice-bath temperature prior to use. When the addition of the halide was complete the reaction mixture was refluxed with stirring for one hour. In some subsequent experiments this period of refluxing was omitted with no deleterious result.The solution of 4-chloro-1-methylpiperidine in tetrahydrofuran was dried over calcium hydride at ice-bath temperature prior to use. When the addition of the halide was complete the reaction mixture was refluxed with stirring for one hour. In some subsequent experiments this period of refluxing was omitted with no deleterious result.The solvent was evaporated from the combined benzene extracts to give 33.4 g of a clear light brown resin. Crystallization from an alcohol-water mixture gave 19.5 g of 1-methyl-4-(5-hydroxy-5-dibenzo[a,e]cycloheptatrienyl)- piperidine, MP 156° to 157°C. Two recrystallizations from alcohol-water mixtures followed by two recrystallizations from benzene-hexane mixtures gave analytically pure product, MP 166.7° to 167.7°C.(C) Preparation of 1-Methyl-4-(5-Dibenzo[a,e]Cycloheptatrienylidene)- Piperidine Hydrochloride: 1-Methyl-4-(5-hydroxy-5-dibenzo[a,e] cycloheptatrienyl)-piperidine (3.05 g, 0.01 mol) was dissolved in glacial acetic acid, 15 ml. The solution was saturated with dry hydrogen chloride with external cooling. A white solid separated. Acetic anhydride (3.07 g, 0.03 mol) was added and the mixture heated on the steam bath for one hour. The solid dissolved in the first 5 minutes of the heating period. The reaction mixture was poured into 25 ml of water and the mixture made strongly basic with 10N sodium hydroxide solution. The mixture was extracted 3 times with 50 ml portions of benzene, the combined extracts washed with water and concentrated to a volume of approximately 50 ml. The solution was saturated with dry hydrogen chloride and the white crystalline product collected and dried. The yield of product, MP 251.6° to 252.6°C (dec.) was 2.5 g. Recrystallization from a mixture of absolute alcohol and absolute ether gave a product, MP 252.6° to 253.6°C. A sample was analyzed after drying for 7 hours at 110°C over phosphorus pentoxide in vacuo. (D) Preparation of 1-Methyl-4-(5-Dibenzo[a,e]Cycloheptatrienylidene)- Piperidine: The hydrochloride salt, 4.3 g, was suspended in 100 ml of warm water and the mixture made strongly alkaline by the addition of 15 ml of 5% sodium hydroxide. The mixture was extracted with four 50 ml portions of benzene and the extracts dried over sodium sulfate. Evaporation of the benzene on the steam-bath at reduced pressure left 3.7 g (97%) of the base,MP 110.3° to 111.3°C. Recrystallization from a mixture of alcohol and water gave product, MP 112.3° to 113.3°C.

Brand name

Periactin (Merck);Anarexal;Antegan;Apeplus;Brantina;Brantine;Carnigol;Carpantin;Ciplactin;Cipractin;Cipro n;Ciprocort;Cyrasarl;Estialim;Histatets;Ifrasarl;Kontrast u;Naidoretico;Nurdelin;Nuttriben;Oractine;Orexigen;Periactol;Perideca;Pranzo;Reparal carnitina;Siglatan;Sigloton;Sipraktin;Siprodin;Vimicon.

Therapeutic Function

Antipruritic, Antihistaminic, Appetite stimulant

World Health Organization (WHO)

Cyproheptadine, an antihistamine with anticholinergic and serotonin-antagonist properties, was introduced in 1961 for the symptomatic relief of allergy and was subsequently used as an appetite stimulant. In 1982 the drug was prohibited in Bangladesh because of its misuse as an appetite stimulant due to inappropriate promotion. Cyproheptadine remains widely available and the current marketing policy of the major manufacturer requires that it should be used as an appetite stimulant only under the supervision of a physician who should be assured that adequate food is available.

Safety Profile

Poison by ingestion, intraperitoneal, subcutaneous and intravenous routes. Experimental teratogenic and reproductive effects. When heated to decomposition it emits toxic fumes of NOx.

Synthesis

Cyproheptadine, 4-(dibenzo[a,d]cyclohepten-5-ylidene)-1-methylpiperidine (16.1.21), is synthesized by reacting 1-methyl-4-magnesiumchloropiperidine with 5H-dibeno[a,d]cycloheptene-5-one, which forms carbinol (16.1.20), the dehydration of which in an acidic medium leads to the formation of cyproheptadine (16.1.21).

Check Digit Verification of cas no

The CAS Registry Mumber 129-03-3 includes 6 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 3 digits, 1,2 and 9 respectively; the second part has 2 digits, 0 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 129-03:
(5*1)+(4*2)+(3*9)+(2*0)+(1*3)=43
43 % 10 = 3
So 129-03-3 is a valid CAS Registry Number.
InChI:InChI=1/C21H21N.ClH/c1-22-14-12-18(13-15-22)21-19-8-4-2-6-16(19)10-11-17-7-3-5-9-20(17)21;/h2-11H,12-15H2,1H3;1H

129-03-3SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 19, 2017

Revision Date: Aug 19, 2017

1.Identification

1.1 GHS Product identifier

Product name cyproheptadine

1.2 Other means of identification

Product number -
Other names cyproheptadiene

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:129-03-3 SDS

129-03-3Synthetic route

5-(1-methyl-4-piperidyl)-5H-dibenzocyclohepten-5-ol
3967-32-6

5-(1-methyl-4-piperidyl)-5H-dibenzocyclohepten-5-ol

cyproheptadine
129-03-3

cyproheptadine

Conditions
ConditionsYield
With formic acid at 100℃; for 2h;99%
With hydrogenchloride; acetic acid at 120℃; for 2h;83%
With formic acid for 1h; Heating; Yield given;
ethyl 4-(5H-dibenzocyclohepten-5-ylidene)-1-piperidinecarboxylate
121138-82-7

ethyl 4-(5H-dibenzocyclohepten-5-ylidene)-1-piperidinecarboxylate

cyproheptadine
129-03-3

cyproheptadine

Conditions
ConditionsYield
With lithium aluminium tetrahydride In tetrahydrofuran for 2h; Heating; Yield given;
(1-methyl-4-piperidyl)magnesium chloride
63463-36-5

(1-methyl-4-piperidyl)magnesium chloride

cyproheptadine
129-03-3

cyproheptadine

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: 76 percent / tetrahydrofuran / 70 °C
2: 83 percent / HOAc, conc. HCl / 2 h / 120 °C
View Scheme
dibenzosuberenon
2222-33-5

dibenzosuberenon

cyproheptadine
129-03-3

cyproheptadine

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: 76 percent / tetrahydrofuran / 70 °C
2: 83 percent / HOAc, conc. HCl / 2 h / 120 °C
View Scheme
Multi-step reaction with 2 steps
1: 60 percent / TiCl3 / 1,2-dimethoxy-ethane
2: LiAlH4 / tetrahydrofuran / 2 h / Heating
View Scheme
N-ethoxycarbonyl-4-piperidone
29976-53-2

N-ethoxycarbonyl-4-piperidone

cyproheptadine
129-03-3

cyproheptadine

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: 60 percent / TiCl3 / 1,2-dimethoxy-ethane
2: LiAlH4 / tetrahydrofuran / 2 h / Heating
View Scheme
cyproheptadine
129-03-3

cyproheptadine

chloroformic acid ethyl ester
541-41-3

chloroformic acid ethyl ester

ethyl 4-(5H-dibenzocyclohepten-5-ylidene)-1-piperidinecarboxylate
121138-82-7

ethyl 4-(5H-dibenzocyclohepten-5-ylidene)-1-piperidinecarboxylate

Conditions
ConditionsYield
In toluene for 5h; Heating;94%
In hexane; toluene
In toluene for 3h; Reflux;
cyproheptadine
129-03-3

cyproheptadine

ether-pet ether

ether-pet ether

4-(10,11-dihydro-5H-dibenzocyclohepten-5-ylidene)-1-methylpiperidine
21081-07-2

4-(10,11-dihydro-5H-dibenzocyclohepten-5-ylidene)-1-methylpiperidine

Conditions
ConditionsYield
With hydrogen In ethanol; acetic acid94%
cyproheptadine
129-03-3

cyproheptadine

1-bromo-4-tert-butylbenzene
3972-65-4

1-bromo-4-tert-butylbenzene

C31H33N

C31H33N

Conditions
ConditionsYield
With PdCl(1,4-bis(diphenylphosphino)butane)(C3H5); potassium acetate In N,N-dimethyl acetamide at 150℃; for 48h; regioselective reaction;72%
cyproheptadine
129-03-3

cyproheptadine

meta-bromotoluene
591-17-3

meta-bromotoluene

C28H27N

C28H27N

Conditions
ConditionsYield
With PdCl(1,4-bis(diphenylphosphino)butane)(C3H5); potassium acetate In N,N-dimethyl acetamide at 150℃; for 48h; regioselective reaction;63%
cyproheptadine
129-03-3

cyproheptadine

2-methylphenyl bromide
95-46-5

2-methylphenyl bromide

C28H27N

C28H27N

Conditions
ConditionsYield
With PdCl(1,4-bis(diphenylphosphino)butane)(C3H5); potassium acetate In N,N-dimethyl acetamide at 150℃; for 48h; regioselective reaction;55%
bromobenzene
108-86-1

bromobenzene

cyproheptadine
129-03-3

cyproheptadine

C27H25N

C27H25N

Conditions
ConditionsYield
With PdCl(1,4-bis(diphenylphosphino)butane)(C3H5); potassium acetate In N,N-dimethyl acetamide at 150℃; for 4h; regioselective reaction;51%
1-bromo-4-methoxy-benzene
104-92-7

1-bromo-4-methoxy-benzene

cyproheptadine
129-03-3

cyproheptadine

C28H27NO

C28H27NO

Conditions
ConditionsYield
With PdCl(1,4-bis(diphenylphosphino)butane)(C3H5); potassium acetate In N,N-dimethyl acetamide at 150℃; for 4h; regioselective reaction;48%
cyproheptadine
129-03-3

cyproheptadine

3-methoxyphenyl bromide
2398-37-0

3-methoxyphenyl bromide

C28H27NO

C28H27NO

Conditions
ConditionsYield
With PdCl(1,4-bis(diphenylphosphino)butane)(C3H5); potassium acetate In N,N-dimethyl acetamide at 150℃; for 48h; regioselective reaction;47%
cyproheptadine
129-03-3

cyproheptadine

4-bromo-1,1'-biphenyl
92-66-0

4-bromo-1,1'-biphenyl

C33H29N

C33H29N

Conditions
ConditionsYield
With PdCl(1,4-bis(diphenylphosphino)butane)(C3H5); potassium acetate In N,N-dimethyl acetamide at 150℃; for 16h; regioselective reaction;45%
cyproheptadine
129-03-3

cyproheptadine

1-Bromonaphthalene
90-11-9

1-Bromonaphthalene

C31H27N

C31H27N

Conditions
ConditionsYield
With PdCl(1,4-bis(diphenylphosphino)butane)(C3H5); potassium acetate In N,N-dimethyl acetamide at 150℃; for 48h; regioselective reaction;44%
cyproheptadine
129-03-3

cyproheptadine

1-bromo-3-chlorobenzene
108-37-2

1-bromo-3-chlorobenzene

C27H24ClN

C27H24ClN

Conditions
ConditionsYield
With PdCl(1,4-bis(diphenylphosphino)butane)(C3H5); potassium acetate In N,N-dimethyl acetamide at 150℃; for 48h; regioselective reaction;41%
cyproheptadine
129-03-3

cyproheptadine

1-bromo-4-fluoronaphthalene
341-41-3

1-bromo-4-fluoronaphthalene

C31H26FN

C31H26FN

Conditions
ConditionsYield
With PdCl(1,4-bis(diphenylphosphino)butane)(C3H5); potassium acetate In N,N-dimethyl acetamide at 150℃; for 48h; regioselective reaction;41%
cyproheptadine
129-03-3

cyproheptadine

para-bromotoluene
106-38-7

para-bromotoluene

C28H27N

C28H27N

Conditions
ConditionsYield
With PdCl(1,4-bis(diphenylphosphino)butane)(C3H5); potassium acetate In N,N-dimethyl acetamide at 150℃; for 48h; Catalytic behavior; Reagent/catalyst; Solvent; Time; regioselective reaction;41%
cyproheptadine
129-03-3

cyproheptadine

4-bromo-N,N-dimethylaniline
586-77-6

4-bromo-N,N-dimethylaniline

C29H30N2

C29H30N2

Conditions
ConditionsYield
With PdCl(1,4-bis(diphenylphosphino)butane)(C3H5); potassium acetate In N,N-dimethyl acetamide at 150℃; for 4h; regioselective reaction;38%
cyproheptadine
129-03-3

cyproheptadine

p-trifluoromethylphenyl bromide
402-43-7

p-trifluoromethylphenyl bromide

C28H24F3N

C28H24F3N

Conditions
ConditionsYield
With PdCl(1,4-bis(diphenylphosphino)butane)(C3H5); potassium acetate In N,N-dimethyl acetamide at 150℃; for 16h; regioselective reaction;38%
cyproheptadine
129-03-3

cyproheptadine

1-Bromo-4-fluorobenzene
460-00-4

1-Bromo-4-fluorobenzene

C27H24FN

C27H24FN

Conditions
ConditionsYield
With PdCl(1,4-bis(diphenylphosphino)butane)(C3H5); potassium acetate In N,N-dimethyl acetamide at 150℃; for 16h; regioselective reaction;38%
6-bromo-naphthalen-2-ol
15231-91-1

6-bromo-naphthalen-2-ol

cyproheptadine
129-03-3

cyproheptadine

C31H27NO

C31H27NO

Conditions
ConditionsYield
With PdCl(1,4-bis(diphenylphosphino)butane)(C3H5); potassium acetate In N,N-dimethyl acetamide at 150℃; for 4h; regioselective reaction;34%
cyproheptadine
129-03-3

cyproheptadine

4-Bromoveratrole
2859-78-1

4-Bromoveratrole

C29H29NO2

C29H29NO2

Conditions
ConditionsYield
With PdCl(1,4-bis(diphenylphosphino)butane)(C3H5); potassium acetate In N,N-dimethyl acetamide at 150℃; for 48h; regioselective reaction;34%
cyproheptadine
129-03-3

cyproheptadine

4-bromo-4'-hydroxybiphenyl
29558-77-8

4-bromo-4'-hydroxybiphenyl

C33H29NO

C33H29NO

Conditions
ConditionsYield
With PdCl(1,4-bis(diphenylphosphino)butane)(C3H5); potassium acetate In N,N-dimethyl acetamide at 150℃; for 4h; regioselective reaction;32%
bromochlorobenzene
106-39-8

bromochlorobenzene

cyproheptadine
129-03-3

cyproheptadine

C27H24ClN

C27H24ClN

Conditions
ConditionsYield
With PdCl(1,4-bis(diphenylphosphino)butane)(C3H5); potassium acetate In N,N-dimethyl acetamide at 150℃; for 16h; regioselective reaction;31%
cyproheptadine
129-03-3

cyproheptadine

para-chlorotoluene
106-43-4

para-chlorotoluene

C28H27N

C28H27N

Conditions
ConditionsYield
With PdCl(1,4-bis(diphenylphosphino)butane)(C3H5); potassium acetate In N,N-dimethyl acetamide at 150℃; for 16h; regioselective reaction;19%
cyproheptadine
129-03-3

cyproheptadine

3-bromo-1-trifluoromethylbenzene
401-78-5

3-bromo-1-trifluoromethylbenzene

C28H24F3N

C28H24F3N

Conditions
ConditionsYield
With PdCl(1,4-bis(diphenylphosphino)butane)(C3H5); potassium acetate In N,N-dimethyl acetamide at 150℃; for 48h; regioselective reaction;15%
cyproheptadine
129-03-3

cyproheptadine

4-tolyl iodide
624-31-7

4-tolyl iodide

A

(4,4'-dimethyl-1,1'-biphenyl)
613-33-2

(4,4'-dimethyl-1,1'-biphenyl)

B

C28H27N

C28H27N

Conditions
ConditionsYield
With PdCl(1,4-bis(diphenylphosphino)butane)(C3H5); potassium acetate In N,N-dimethyl acetamide at 150℃; for 16h; regioselective reaction;A n/a
B 11%
cyproheptadine
129-03-3

cyproheptadine

cyproheptadine 10,11-epoxide
54191-04-7

cyproheptadine 10,11-epoxide

Conditions
ConditionsYield
With sodium hydroxide; dihydrogen peroxide In acetone; acetonitrile
cyproheptadine
129-03-3

cyproheptadine

carbonochloridic acid 1-chloro-ethyl ester
50893-53-3

carbonochloridic acid 1-chloro-ethyl ester

4-Dibenzo[a,d]cyclohepten-5-ylidene-piperidine-1-carboxylic acid 1-chloro-ethyl ester

4-Dibenzo[a,d]cyclohepten-5-ylidene-piperidine-1-carboxylic acid 1-chloro-ethyl ester

Conditions
ConditionsYield
With sodium carbonate In 1,2-dichloro-ethane 1) 0 deg C, 2) reflux;
cyproheptadine
129-03-3

cyproheptadine

4-(5H-dibenzo[a,d]cyclohepten-5-ylidene)piperidine
14051-46-8

4-(5H-dibenzo[a,d]cyclohepten-5-ylidene)piperidine

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: Na2CO3 / 1,2-dichloro-ethane / 1) 0 deg C, 2) reflux
2: 1) CH3OH, 2) NaOH / 1) r.t., 15 min, 50 deg C, 15 min, 2) water
View Scheme
Multi-step reaction with 2 steps
1: toluene / 3 h / Reflux
2: potassium hydroxide; water / ethanol / Reflux
View Scheme
cyproheptadine
129-03-3

cyproheptadine

4-(4-Dibenzo[a,d]cyclohepten-5-ylidene-piperidin-1-yl)-butylamine
175692-31-6

4-(4-Dibenzo[a,d]cyclohepten-5-ylidene-piperidin-1-yl)-butylamine

Conditions
ConditionsYield
Multi-step reaction with 4 steps
1: Na2CO3 / 1,2-dichloro-ethane / 1) 0 deg C, 2) reflux
2: 1) CH3OH, 2) NaOH / 1) r.t., 15 min, 50 deg C, 15 min, 2) water
3: 80 percent / Na2CO3, KI / acetonitrile; dimethylformamide / Heating
4: 62 percent / LiAlH4 / tetrahydrofuran; diethyl ether / 2 h / Ambient temperature
View Scheme

129-03-3Related news

Reversed-phase high performance liquid chromatographic determination of Cyproheptadine (cas 129-03-3) from urine by solid-phase extraction09/30/2019

A simple, sensitive and reliable high-performance liquid chromatographic method for the determination of cyproheptadine in urine by solid-phase extraction (SPE) has been developed. The sample matrix was passed through a pre-conditioned C 1 8 cartridge, washed with methanol-water sol...detailed

Preventive effect of Cyproheptadine (cas 129-03-3) hydrochloride in refractory patients with frequent migraine09/28/2019

Cyproheptadine hydrochloride (CH) is rarely used to treat adult patients with migraine in Japan because it causes sleepiness. In this study, we investigated the preventive effect of CH in 12 patients who had failed to respond to conventional preventive treatments among 103 migraine patients trea...detailed

Quantification of Cyproheptadine (cas 129-03-3) in human plasma by high‐performance liquid chromatography coupled to electrospray tandem mass spectrometry in a bioequivalence study09/27/2019

A rapid, sensitive and specific method to quantify cyproheptadine in human plasma using amitriptyline as the internal standard (IS) is described. The analyte and the IS were extracted from plasma by liquid‐liquid extraction using a diethyl‐ether/dichloromethane (70/30; v/v) solvent. After remo...detailed

Interaction of Cyproheptadine (cas 129-03-3) hydrochloride with human serum albumin using spectroscopy and molecular modeling methods09/26/2019

The interaction between cyproheptadine hydrochloride (CYP) and human serum albumin (HSA) was investigated by fluorescence spectroscopy, UV–vis absorption spectroscopy, Fourier transform infrared spectroscopy (FT‐IR) and molecular modeling at a physiological pH (7.40). Fluorescence of HSA was q...detailed

129-03-3Relevant articles and documents

Structure-activity relationships in the cyproheptadine series.

Engelhardt,Zell,Saari,Christy,Colton,Stone,Stavorski,Wenger,Ludden

, p. 829 - 835 (1965)

-

Synthesis and pharmacology of combined histamine H1-/H2-receptor antagonists containing diphenhydramine and cyproheptadine derivatives

Wolf, Cornelia,Schunack, Walter

, p. 87 - 94 (2007/10/02)

The classical histamine H1-receptor antagonists diphenhydramine (3a) and cyproheptadine (9) and their derivatives (3b-d, 10) were connected with a 2-guanidinothiazole containing structure (28) derived from the H2-receptor antagonist tiotidine in order to obtain combined H1/H2-receptor antagonists. The two moieties were not directly linked together, but were separated by a polymethylene spacer and a polar group (nitroethenediamine or urea). Thus 12 compounds were obtained that proved in vitro to possess high H1- and H2-receptor antagonist activity at the isolated guinea-pig ileum (H1) and the isolated guinea-pig right atrium (H2), respectively. The incorporation of the diphenhydramine as well as the cyproheptadine component provides high affinity to H1-receptors. The tricyclic cyproheptadine and its 10,11-dihydro derivative (30-32, 34), however, cause a decrease of H2-receptor antagonist potency compared to the diphenhydramines (29a-d, 33a-d). Using nitroethenediamine as the polar group is apparently more favourable to H1- and H2-receptor affinity as the urea function. All compounds elicit a dual mode of competitive and noncompetitive antagonism. Among the novel compounds the nitroethenediamines with 4-fluoro- or 4-methyl-substituted diphenhydramine as H1-receptor antagonist moiety (29c, d) display the most potent H1- and H2-receptor antagonist effects. The presented concept is a very promising way to combine H1- and H2-receptor antagonist properties in one molecule.

UNUSUAL REDUCTIONS INDUCED BY FORMIC ACID

Loughhead, David G.

, p. 5701 - 5702 (2007/10/02)

Treatment of xanthene carbinol 1a or xanthenylidene derivative 2a with refluxing formic acid unexpectedly gave dihydro compound 3a.Thioxanthene and acridine carbinols 1b and 1c and acridinylidene derivative 2c were also partially reduced when treated with formic acid.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 129-03-3